Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-11-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - NTI 4 pages 14.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Neurotech International Limited. It includes specifics such as the security code, number of securities ceased, reason for cessation (expiry of options), and updated issued capital figures. The document is a formal announcement to the ASX about changes in the company's issued securities, specifically the cessation of certain options due to expiry. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an official notification about securities cessation, which aligns with announcements related to share capital changes or securities status updates. Given the nature of the content, the most appropriate classification is 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including cessation of securities.
2024-11-19 English
Positive Genomic Effects of NTI164 in PANDAS/PANS Patients 3 pages 223.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 15 November 2024 from Neurotech International Limited. It reports the primary results of a genomic analysis from a Phase I/II clinical trial on PANDAS/PANS patients treated with NTI164. The content focuses on clinical trial results, scientific findings, and patient benefits, with no financial statements or regulatory filings. It is a detailed announcement of clinical trial data and scientific results rather than a financial report, earnings release, or management discussion. The document is longer than 5,000 characters and contains substantive scientific data but no financial data. It is not a report publication announcement since it contains detailed results, not just a notice of report availability. The document fits best as a Regulatory Filings (RNS) type, as it is a general regulatory announcement of clinical trial results made to the stock exchange (ASX).
2024-11-14 English
New Scientific Publication Highlights Benefits of NTI164 2 pages 169.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 12 November 2024 from Neurotech International Limited. It discusses the publication of new pre-clinical scientific data related to their drug NTI164, highlighting research findings and referencing a peer-reviewed journal article. The content focuses on scientific and clinical trial results rather than financial data or regulatory filings. There is no indication of financial statements, management discussion, voting results, or regulatory compliance documents. The document is an announcement of a scientific publication and clinical trial data, not a financial report or regulatory filing. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2024-11-11 English
Neurotech Appoints Dr Anthony Filippis as MD/CEO 4 pages 132.7KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 11 November 2024 regarding the appointment of Dr Anthony Filippis as Managing Director and CEO of Neurotech International Limited. It details his background, the terms of his appointment, remuneration, and incentive options. There are no financial statements, earnings data, or regulatory filings related to financial results. The content focuses on management changes at the company, specifically the appointment of a new CEO. This fits the category of Board/Management Information (MANG). The document length is 9447 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement. Therefore, the correct classification is MANG with high confidence.
2024-11-10 English
Proposed issue of securities - NTI 6 pages 22.6KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard ASX announcement format used to notify the market of a proposed issue of securities, specifically options in this case. It details the number of securities, the type (options), the proposed issue date, and the purpose (equity incentive to the incoming CEO). The document does not contain financial statements or detailed financial performance data but is an announcement regarding a capital raising or share issue event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Hence, the classification is CAP with high confidence.
2024-11-10 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 436.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 30 September 2024' and contains detailed clinical updates, trial results, regulatory submissions, and financial information such as cash on hand. It covers a quarterly period (Q1 FY2025) and includes substantive financial and operational data. The presence of an Appendix 4C Quarterly Cash Flow Report further supports that this is a comprehensive quarterly report. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2024-10-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.